Versant Capital Management’s Edwards Lifesciences EW Stock Holding History

Versant Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$485K	Buy	5,366 +2,380	+80%	+$199K	0.04%	305
2026 Q1	$239K	Buy	2,986 +286	+11%	+$23.6K	0.02%	518
2025 Q4	$230K	Sell	2,700 -37	-1%	-$3.04K	0.03%	449
2025 Q3	$213K	Buy	2,737 +883	+48%	+$69K	0.03%	451
2025 Q2	$145K	Buy	1,854 +156	+9%	+$11.6K	0.02%	542
2025 Q1	$123K	Buy	1,698 +145	+9%	+$10.4K	0.02%	563
2024 Q4	$115K	Buy	1,553 +786	+102%	+$55K	0.02%	268
2024 Q3	$50.6K	Buy	767 +283	+58%	+$20.6K	0.01%	447
2024 Q2	$44.7K	Buy	484 +326	+206%	+$28.9K	0.01%	414
2024 Q1	$15.1K	Buy	158 +112	+243%	+$9.41K	﹤0.01%	598
2023 Q4	$3.51K	Buy	46 +10	+28%	+$696	﹤0.01%	1108
2023 Q3	$2.49K	Sell	36 -3	-8%	-$241	﹤0.01%	1229
2023 Q2	$3.68K	Buy	39 +9	+30%	+$782	﹤0.01%	1151
2023 Q1	$2.48K	Hold	30	–	–	﹤0.01%	1205
2022 Q4	$2.24K	Sell	30 -9	-23%	-$694	﹤0.01%	1115
2022 Q3	$3K	Sell	39 -16	-29%	-$1.54K	﹤0.01%	974
2022 Q2	$5K	Hold	55	–	–	﹤0.01%	851
2022 Q1	$6K	Sell	55 -22	-29%	-$2.47K	﹤0.01%	823
2021 Q4	$10K	Hold	77	–	–	﹤0.01%	709
2021 Q3	$9K	Sell	77 -16	-17%	-$1.83K	﹤0.01%	722
2021 Q2	$10K	Hold	93	–	–	﹤0.01%	707
2021 Q1	$8K	Hold	93	–	–	﹤0.01%	863
2020 Q4	$8K	Hold	93	–	–	﹤0.01%	783
2020 Q3	$7K	Hold	93	–	–	﹤0.01%	757
2020 Q2	$6K	Hold	93	–	–	﹤0.01%	782
2020 Q1	$5K	Buy	93 +24	+35%	+$1.73K	﹤0.01%	766
2019 Q4	$5K	Hold	69	–	–	﹤0.01%	917
2019 Q3	$5K	Hold	69	–	–	﹤0.01%	938
2019 Q2	$4K	Sell	69 -501	-88%	-$30.3K	﹤0.01%	1016
2019 Q1	$36K	Hold	570	–	–	0.02%	368
2018 Q4	$29K	Hold	570	–	–	0.01%	388
2018 Q3	$33K	Sell	570 -12	-2%	-$587	0.01%	425
2018 Q2	$28K	Hold	582	–	–	0.01%	479
2018 Q1	$27K	Hold	582	–	–	0.01%	499
2017 Q4	$21K	Hold	582	–	–	0.01%	632
2017 Q3	$21K	Hold	582	–	–	0.01%	563
2017 Q2	$22K	Sell	582 -66	-10%	-$2.41K	0.01%	553
2017 Q1	$20K	Hold	648	–	–	0.01%	581
2016 Q4	$20K	Hold	648	–	–	0.01%	588
2016 Q3	$26K	Sell	648 -21	-3%	-$791	0.01%	480
2016 Q2	$22K	Hold	669	–	–	0.01%	511
2016 Q1	$19K	Buy	669 +51	+8%	+$1.41K	0.01%	535
2015 Q4	$16K	Buy	+618	New	+$16K	0.01%	580

Other funds holding EW

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

NONA

Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SIM

Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

FFM

Fisher Funds Management Auckland, New Zealand $3.52B AUM 17.59% 1-Year Est. Return

Versant Capital Management's EW Position: Q2 2026 in Review

Versant Capital Management increased its Edwards Lifesciences (EW) stake by 80% in Q2 2026, buying an estimated $199K and bringing the position to 5,366 shares worth $485K. The position accounts for 0.04% of the portfolio, ranked #305.

Versant Capital Management first reported a position in EW in Q4 2015 and has held it in 43 quarters since. 287 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Versant Capital Management held 5,366 shares of Edwards Lifesciences worth $485K as of Q2 2026.
Versant Capital Management bought 2,380 Edwards Lifesciences shares in Q2 2026, an estimated $199K.
Edwards Lifesciences made up 0.04% of Versant Capital Management's portfolio in Q2 2026, its #305 holding.
Versant Capital Management first reported a position in Edwards Lifesciences in Q4 2015 and has held it in 43 quarters since.
287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.